var data={"title":"Loperamide: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Loperamide: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6477?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=loperamide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Loperamide: Patient drug information&quot;</a> and <a href=\"topic.htm?path=loperamide-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Loperamide: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51062736\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Loperamide Safety Alert</span>\n      <span class=\"collapsible-date\">January 2018</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-top:2em;\">The FDA continues to receive reports of serious heart problems and deaths with use of higher than recommended doses of loperamide, primarily among people who are intentionally misusing or abusing the product. To encourage safe use, the FDA is working with loperamide manufacturers to use blister packs or other single-dose packaging and to limit the number of doses in a package.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Providers should counsel patients to take loperamide only as prescribed or according to the OTC Drug Facts label, and advise patients that drug interactions with commonly used medicines may increase the risk of serious cardiac events.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Further information can be found at <a target=\"_blank\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm594403.htm&amp;token=8RYIFfyLhIBYEqeX7m6uPG6jnWVdkJ4rlHSePh6VTLmOhyJ+Nznygvd8P/bvekGQX5dujULjGxVyhOXYIw1Bh9i85TeA+aP+CDg+ZuBgVnkMgZe9FQL16ZtaFtrRrlR70/GkkQYj1qvXyZoI5PgDxw==&amp;TOPIC_ID=9571\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm594403.htm</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49184879\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Torsades de pointes and sudden death</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Cases of torsades de pointes, cardiac arrest, and death have been reported with the use of a higher than recommended dosage of loperamide.</p>\n        <p style=\"text-indent:0em;\">Loperamide is contraindicated in pediatric patients &lt;2 years of age.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Avoid dosages higher than recommended in adults and pediatric patients &ge;2 years due to the risk of serious cardiac adverse reactions.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189683\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Anti-Diarrheal [OTC];</li>\n      <li>Diamode [OTC];</li>\n      <li>Imodium A-D [OTC];</li>\n      <li>Loperamide A-D [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189684\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Loperamide;</li>\n      <li>Diarr-Eze;</li>\n      <li>Dom-Loperamide;</li>\n      <li>Imodium;</li>\n      <li>Loperacap;</li>\n      <li>Novo-Loperamide;</li>\n      <li>PMS-Loperamine;</li>\n      <li>Rho-Loperamine;</li>\n      <li>Rhoxal-loperamide;</li>\n      <li>Riva-Loperamide;</li>\n      <li>Sandoz-Loperamide</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189727\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidiarrheal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189687\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute diarrhea:</b> Oral: Initial: 4 mg, followed by 2 mg after each loose stool (maximum: 16 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic diarrhea:</b> Oral: Initial: 4 mg, followed by 2 mg after each loose stool (maximum: 16 mg/day); maintenance dose should be slowly titrated downward to minimum required to control symptoms (usual: 4 to 8 mg/day as a single dose or in divided doses; maximum: 16 mg/day). If clinical improvement is not observed after at least 10 days of treatment with 16 mg/day, symptoms are unlikely to be controlled by further administration; treatment may be continued if diarrhea cannot be adequately controlled with diet or other therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Traveler's diarrhea:</b> Oral: Initial: 4 mg after first loose stool, followed by 2 mg after each subsequent stool (maximum dose: 16 mg/day [OTC: 8 mg/day]); (duration of therapy: &le;48 hours); in patients with moderate-to-severe illness receiving an antibiotic, loperamide is recommended as adjunctive therapy to decrease duration of diarrhea (ACG [Riddle 2016]; however, acquisition of extended-spectrum-beta-lactamase-producing pathogens may be more common when loperamide and antibiotics are coadministered (CDC 2018). Do not use loperamide in cases of dysentery (IDSA [Hill 2006]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cancer treatment-induced diarrhea (off-label use):</b> Oral: 4 mg, followed by 2 mg every 4 hours or after each loose stool; Maximum: 16 mg/day (Benson 2004; Morturano 2012; NCCN Palliative Care Guidelines [Siegel 2017]) <b>or</b> 4 mg followed by 2 mg every 2 hours (4 mg every 4 hours at night) until 12 hours have passed without a loose bowel movement (Sharma 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Irinotecan-induced delayed diarrhea (off-label use):</b> Oral: 4 mg after first loose or frequent bowel movement, then 2 mg every 2 hours (4 mg every 4 hours at night) until 12 hours have passed without a bowel movement (Rothenberg 1996).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189704\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=loperamide-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Loperamide: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute diarrhea: </b>Oral: Children &ge;2 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial (first 24 hours):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">2 to 5 years (13 to 20 kg): 1 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">6 to 8 years (20 to 30 kg): 2 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">8 to 12 years (&gt;30 kg): 2 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;13 years: Refer to adult dosing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">2 to 5 years (13 to 20 kg): After the first 24 hours, 0.1 mg/kg/dose after each loose stool (maximum: 3 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">6 to 8 years (20 to 30 kg): After the first 24 hours, 0.1 mg/kg/dose after each loose stool (maximum: 4 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">8 to 12 years (&gt;30 kg): After the first 24 hours, 0.1 mg/kg/dose after each loose stool (maximum: 6 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;13 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Traveler's diarrhea (OTC labeling):</b> Oral: Children &ge;6 years and Adolescents: <b>Note:</b> Weight-based dosing is preferred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">6 to 8 years (22 to 26 kg): 2 mg after first loose stool, followed by 1 mg after each subsequent stool (maximum dose: 4 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">9 to 11 years (27 to 43 kg): 2 mg after first loose stool, followed by 1 mg after each subsequent stool (maximum dose: 6 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;12 years: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189688\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14186587\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127378\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189665\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imodium A-D: 2 mg [contains brilliant blue fcf (fd&amp;c blue #1), peg-40 hydrogenated castor oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Liquid, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imodium A-D: 1 mg/7.5 mL (30 mL [DSC], 120 mL, 240 mL, 360 mL [DSC]) [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow), propylene glycol, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imodium A-D: 1 mg/7.5 mL (120 mL, 240 mL) [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow), propylene glycol, sodium benzoate; mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/5 mL (5 mL, 10 mL, 118 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/7.5 mL (120 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anti-Diarrheal: 2 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anti-Diarrheal: 2 mg [contains brilliant blue fcf (fd&amp;c blue #1), corn starch, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anti-Diarrheal: 2 mg [scored; contains brilliant blue fcf (fd&amp;c blue #1), corn starch, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anti-Diarrheal: 2 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anti-Diarrheal: 2 mg [scored; contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anti-Diarrheal: 2 mg [contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diamode: 2 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imodium A-D: 2 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imodium A-D: 2 mg [DSC] [scored; contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imodium A-D: 2 mg [DSC] [contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imodium A-D: 2 mg [scored; contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Loperamide A-D: 2 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imodium A-D: 2 mg [DSC] [contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189652\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49184881\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with plenty of clear fluids to prevent dehydration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chewable tablets: Administer on an empty stomach (1 hour before or 2 hours after a meal).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution: Shake well before administering dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189668\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diarrhea:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rx labeling: Control and symptomatic relief of chronic diarrhea associated with inflammatory bowel disease in adults; acute nonspecific diarrhea in patients &ge;2 years; to reduce volume of ileostomy discharge</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">OTC labeling: Control of symptoms of diarrhea, including Traveler's diarrhea</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25726842\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Traveler&rsquo;s diarrhea; Cancer treatment-induced diarrhea</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189734\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imodium A-D may be confused with Indocin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Loperamide may be confused with furosemide, Lomotil</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Indiaral [France] may be confused with Inderal and Inderal LA brand names for propranolol [US, Canada, and multiple international markets]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lomotil: Brand name for loperamide [Mexico, Philippines], but also the brand name for diphenoxylate [US, Canada, and multiple international markets]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lomotil [Mexico, Phillipines] may be confused with Ludiomil brand name for maprotiline [multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189659\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Constipation (2% to 5%), abdominal cramps (&le;3%), nausea (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal discomfort, abdominal distention, abdominal pain, anaphylactic shock, anaphylactoid reaction, angioedema, bullous rash (rare), drowsiness, dyspepsia, erythema multiforme (rare), fatigue, flatulence, hypersensitivity reaction, megacolon, paralytic ileus, pruritus, skin rash, Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare), toxic megacolon, urinary retention, urticaria, vomiting, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189671\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to loperamide or any component of the formulation; abdominal pain without diarrhea; children &lt;2 years; acute dysentery; acute ulcerative colitis; bacterial enterocolitis (caused by <i>Salmonella</i>, <i>Shigella</i>, and <i>Campylobacter</i>); pseudomembranous colitis associated with broad-spectrum antibiotic use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC labeling: When used for self-medication, do not use if stool is bloody or black.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for antidiarrheals is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189656\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Allergic reactions: Rare cases of anaphylaxis and anaphylactic shock have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May cause drowsiness or dizziness, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI effects: Discontinue promptly if constipation, abdominal pain, abdominal distension, blood in stool, or ileus develop. Do not use when peristalsis inhibition should be avoided due to potential for ileus, megacolon and/or toxic megacolon.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Torsades de pointes and sudden death: <b>[US Boxed Warning]: Cases of torsades de pointes, cardiac arrest, and death have been reported with the use of a higher than recommended dosage. Contraindicated in pediatric patients &lt;2 years. Avoid dosages higher than recommended in patients &ge;2 years due to the risk of serious cardiac adverse reactions.</b> Cases of syncope and ventricular tachycardia have been reported in adults receiving the recommended dose of loperamide. Cases of cardiac arrest, syncope, and respiratory depression have been reported in pediatric patients &lt;2 years. Avoid use in patients with risk factors for QT prolongation (eg, congenital long QT syndrome, history of cardiac arrhythmias or other cardiac conditions, elderly, electrolyte abnormalities) and in combination with others drugs known to prolong the QT interval.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; AIDS patients: Stop therapy at the first sign of abdominal distention; cases of toxic megacolon have occurred in AIDS patients with infectious colitis (due to viral or bacterial pathogens).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment due to reduced first-pass metabolism; monitor for signs of CNS toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Special populations:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; may be more susceptible to drug-associated effects on the QT interval.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use with caution in young children as response may be variable because of dehydration. Contraindicated in children &lt;2 years.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Loperamide is a symptom-directed treatment; if an underlying diagnosis is made, other disease-specific treatment may be indicated. Concurrent fluid and electrolyte replacement is often necessary in all age groups depending upon severity of diarrhea.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Duration of use: If diarrhea lasts longer than 2 days, symptoms worsen, or abdominal swelling or bulging develops, discontinue use and consult healthcare provider.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Self medication (OTC use): Consult health care provider prior to using, if taking antibiotics, if pregnant or breastfeeding, or in the presence of fever, mucus in stool, or a history of liver disease. Serious heart problems may occur if taken more than directed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127373\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of P-glycoprotein/ABCB1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189661\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9571&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Loperamide-Loperamide Oxide may increase the serum concentration of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Loperamide-Loperamide Oxide may enhance the constipating effect of Eluxadoline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Loperamide-Loperamide Oxide may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189662\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2127372\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have not been observed in animal reproduction studies. Information related to loperamide use in pregnancy is limited and data is conflicting (Einarson 2000; K&auml;ll&eacute;n 2008). For acute diarrhea in pregnant women, some clinicians recommend oral rehydration and dietary changes; loperamide in small amounts may be used only if symptoms are disabling (Wald 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14186532\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Small amounts of loperamide are present in breast milk (information is based on studies using loperamide oxide, the prodrug of loperamide [Nikodem 1992]). Breastfeeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1623722\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49185057\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;\">Signs of CNS toxicity in patients with hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189655\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Acts directly on circular and longitudinal intestinal muscles, through the opioid receptor, to inhibit peristalsis and prolong transit time; reduces fecal volume, increases viscosity, and diminishes fluid and electrolyte loss; demonstrates antisecretory activity. Loperamide increases tone on the anal sphincter</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189670\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Poor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Poor penetration into brain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via oxidative N-demethylation; CYP2C8 and CYP3A4 (major) and CYP2B6 and CYP2D6 (minor) role in N-demethylation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 9.1 to 14.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Liquid: 2.5 hours; Capsule: ~5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189673\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Imodium A-D Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (24): $11.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Loperamide HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $104.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Imodium A-D Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/7.5 mL (120 mL): $5.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Loperamide HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/5 mL (5 mL): $1.79</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Imodium A-D Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (24): $10.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Loperamide A-D Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (12): $1.88</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189674\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abydium (LK);</li>\n      <li>Albutil (BD);</li>\n      <li>Arret (IE);</li>\n      <li>Beamodium (MY);</li>\n      <li>Betaperamide (ZA);</li>\n      <li>Binaldan (CH);</li>\n      <li>Cicamin (PY);</li>\n      <li>Colidium (ID);</li>\n      <li>Colifilm (AR);</li>\n      <li>Coliper (CL);</li>\n      <li>Colodium (HK);</li>\n      <li>Contem (PY);</li>\n      <li>D-Stop-ratiopharm (LU);</li>\n      <li>Degortkap (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Diadium (ID);</li>\n      <li>Diamide (NZ);</li>\n      <li>Diaperol (MX);</li>\n      <li>Diareze (AU);</li>\n      <li>Diarlop (IN);</li>\n      <li>Diarodil (TH);</li>\n      <li>Diatabs (PH);</li>\n      <li>Diatrol (SG);</li>\n      <li>Dissenten (IT);</li>\n      <li>Donafan (PE);</li>\n      <li>Donamed F (PE);</li>\n      <li>Dyspagon (LU);</li>\n      <li>Elcoman (AR);</li>\n      <li>Fortasec (ES);</li>\n      <li>Gastro-Stop (AU);</li>\n      <li>Gastron (ZA);</li>\n      <li>Harmonise (AU);</li>\n      <li>Hocular (TW);</li>\n      <li>Hrindeks (UA);</li>\n      <li>Imodium (AE, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BS, CH, CI, CN, CO, CY, CZ, DE, DK, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HR, HU, ID, IE, IL, IN, IQ, IR, IS, IT, JM, JO, KE, KW, LB, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SC, SD, SE, SG, SK, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UA, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Imodonil (HK);</li>\n      <li>Imonox (TH);</li>\n      <li>Imosec (BR);</li>\n      <li>Imosen (TW);</li>\n      <li>Imossel (FR);</li>\n      <li>Imotil (LK);</li>\n      <li>Inamid (ID);</li>\n      <li>Lenide-T (ZA);</li>\n      <li>Lockit (ZW);</li>\n      <li>Lodia (ID);</li>\n      <li>Lomedium (VN);</li>\n      <li>Lomid (BD);</li>\n      <li>Lomotil (MX);</li>\n      <li>Loniper (PH);</li>\n      <li>Lopamid (BD, ID);</li>\n      <li>Lopamide (ET, IN);</li>\n      <li>Lopedin (TW);</li>\n      <li>Lopedium (HU, LU);</li>\n      <li>Lopemid (IT);</li>\n      <li>Loper (HK);</li>\n      <li>Loperamid-ratiopharm (LU);</li>\n      <li>Loperamide-Eurogenerics (LU);</li>\n      <li>Loperamide-Generics (LU);</li>\n      <li>Loperamil (HK, SG);</li>\n      <li>Loperhoe (DE);</li>\n      <li>Loperium (BB, BM, BS, BZ, GY, JM, MT, NL, SR, TT);</li>\n      <li>Lopermid (TR);</li>\n      <li>Lopermide (HK);</li>\n      <li>Lopicare (IL);</li>\n      <li>Lopide (BD);</li>\n      <li>Lopmin (KR);</li>\n      <li>Lopodium (QA);</li>\n      <li>Loprex (IL);</li>\n      <li>Loprid (RO);</li>\n      <li>Lopron (PH);</li>\n      <li>Loramide (LK, SG);</li>\n      <li>Lordiar (HR);</li>\n      <li>Lorid (BD);</li>\n      <li>Luobaomai (CN);</li>\n      <li>Motilex (ID);</li>\n      <li>NT-Diorea (HK);</li>\n      <li>Pangetan NF (CO);</li>\n      <li>Paradoxone (ET);</li>\n      <li>Perasian (TH);</li>\n      <li>Permid (PH);</li>\n      <li>Ramide (ET);</li>\n      <li>Regulane (AR);</li>\n      <li>Rexamide (IL);</li>\n      <li>Reximide (MY);</li>\n      <li>Rhomuz (ID);</li>\n      <li>Safe (TW);</li>\n      <li>Salvacolina (ES);</li>\n      <li>Sanpo (TW);</li>\n      <li>Seldiar (HR);</li>\n      <li>Shilshul X2 (IL);</li>\n      <li>Stoperan (UA);</li>\n      <li>Stopit (IL);</li>\n      <li>Suprasec (AR);</li>\n      <li>Tarmin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Toban (PE);</li>\n      <li>Toban F (PE);</li>\n      <li>Undiarrhea (TW);</li>\n      <li>Vacontil (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, JO, KE, KW, LB, LR, MA, ML, MR, MU, MW, MY, NE, NG, OM, QA, SC, SD, SL, SN, TN, TZ, UG, VN, ZM, ZW);</li>\n      <li>Vancotil (SG);</li>\n      <li>Velaral (EC)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abigerges D, Armand JP, Chabot GG, et al, &ldquo;Irinotecan (CPT-11) High-Dose Escalation Using Intensive High-Dose Loperamide to Control Diarrhea,&rdquo; <i>J Natl Cancer Inst</i>, 1994, 86(6):446-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-drug-information/abstract-text/8120919/pubmed\" target=\"_blank\" id=\"8120919\">8120919</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benson AB 3rd, Ajani JA, Catalano RB, et al, &quot;Recommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea,&quot; <i>J Clin Oncol</i>, 2004, 22(14):2918-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-drug-information/abstract-text/15254061/pubmed\" target=\"_blank\" id=\"15254061\">15254061</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention. The pre-travel consultation: travelers' diarrhea. The Yellow Book: CDC health information for international travel, 2018. <a href=\"https://wwwnc.cdc.gov/travel/yellowbook/2018/the-pre-travel-consultation/travelers-diarrhea\" target=\"_blank\">https://wwwnc.cdc.gov/travel/yellowbook/2018/the-pre-travel-consultation/travelers-diarrhea</a>. Updated June 13, 2017. Accessed September 6, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Einarson A, Mastroiacovo P, Arnon J, et al, &quot;Prospective, Controlled, Multicentre Study of Loperamide in Pregnancy,&quot; <i>Can J Gastroenterol</i>, 2000, 14(3):185-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-drug-information/abstract-text/10758415/pubmed\" target=\"_blank\" id=\"10758415\">10758415</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ericsson CD, &quot;Nonantimicrobial Agents in the Prevention and Treatment of Traveler's Diarrhea,&quot; <i>Clin Infect Dis</i>, 2005, 41(Suppl 8):557-63.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ericsson CD and Johnson PC, &ldquo;Safety and Efficacy of Loperamide,&rdquo; <i>Am J Med</i>, 1990, 88(6A):10S-14S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-drug-information/abstract-text/2192552/pubmed\" target=\"_blank\" id=\"2192552\">2192552</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hill DR, Ericsson CD, Pearson RD, et al. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2006;43(12):1499-1539.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-drug-information/abstract-text/17109284/pubmed\" target=\"_blank\" id=\"17109284\">17109284</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imodium A-D (loperamide) caplets [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare Dicision; received April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imodium A-D (loperamide) oral solution [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare Dicision; received April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imodium A-D (loperamide) tablets [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare Dicision; received April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K&auml;ll&eacute;n B, Nilsson E, and Otterblad Olausson P, &quot;Maternal Use of Loperamide in Early Pregnancy and Delivery Outcome,&quot; <i>Acta Paediatr</i>, 2008, 97(5):541-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-drug-information/abstract-text/18394096/pubmed\" target=\"_blank\" id=\"18394096\">18394096</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kornblau S, Benson AB, Catalano R, et al, &ldquo;Management of Cancer Treatment-Related Diarrhea. Issues and Therapeutic Strategies,&rdquo; <i>J Pain Symptom Manage</i>, 2000, 19(2):118-29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-drug-information/abstract-text/10699539/pubmed\" target=\"_blank\" id=\"10699539\">10699539</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loperamide hydrochloride [prescribing information]. Morgantown,WV: Mylan Pharmaceuticals Inc; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Morturano R. Management of chemotherapy-induced diarrhea. OncoLink. https://www.oncolink.org/healthcare-professionals/o-pro-portal/articles-about-cancer-treatment-and-medications/management-of-chemotherapy-induced-diarrhea. Updated October 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nikodem VC and Hofmeyr GJ, &quot;Secretion of the Antidiarrhoeal Agent Loperamide Oxide in Breast Milk,&quot; <i>Eur J Clin Pharmacol</i>, 1992, 42(6):695-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-drug-information/abstract-text/1623917/pubmed\" target=\"_blank\" id=\"1623917\">1623917</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27068718\"></a>Riddle MS, DuPont HL, Connor BA. ACG Clinical Guideline: Diagnosis, treatment, and prevention of acute diarrheal infections in adults. <i>Am J Gastroenterol.</i> 2016;111(5):602-622.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-drug-information/abstract-text/27068718/pubmed\" target=\"_blank\" id=\"27068718\">27068718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rothenberg ML, Eckardt JR, Kuhn JG, et al, &quot;Phase II Trial of Irinotecan in Patients With Progressive or Rapidly Recurrent Colorectal Cancer,&quot; <i>J Clin Oncol</i>, 1996, 14(4):1128-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-drug-information/abstract-text/8648367/pubmed\" target=\"_blank\" id=\"8648367\">8648367</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sharma R, Tobin P, and Clarke SJ, &ldquo;Management of Chemotherapy-Induced Nausea, Vomiting, Oral Mucositis, and Diarrhoea,&rdquo; <i>Lancet Oncol</i>, 2005, 6(2):93-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-drug-information/abstract-text/15683818/pubmed\" target=\"_blank\" id=\"15683818\">15683818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Siegel.2017\"></a>Siegel RL, Ferris FD, Becker G, et al. NCCN Clinical Practice Guideline in Oncology: Palliative care. Epub March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wald A, &quot;Constipation, Diarrhea, and Symptomatic Hemorrhoids During Pregnancy,&quot; <i>Gastroenterol Clin North Am</i>, 2003, 32(1):309-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/loperamide-drug-information/abstract-text/12635420/pubmed\" target=\"_blank\" id=\"12635420\">12635420</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9571 Version 200.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F51062736\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F49184879\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F189683\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F189684\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F189727\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F189687\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F189704\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F189688\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F14186587\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F2127378\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F189665\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F189652\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F49184881\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F189668\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25726842\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F189734\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F189659\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F189671\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F189656\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F2127373\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F189661\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F189662\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2127372\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F14186532\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F1623722\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F49185057\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F189655\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F189670\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F189673\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F189674\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9571|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=loperamide-patient-drug-information\" class=\"drug drug_patient\">Loperamide: Patient drug information</a></li><li><a href=\"topic.htm?path=loperamide-pediatric-drug-information\" class=\"drug drug_pediatric\">Loperamide: Pediatric drug information</a></li></ul></div></div>","javascript":null}